235
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy

, , , , , , , & show all
Pages 495-498 | Received 03 May 2022, Accepted 11 Nov 2022, Published online: 17 Nov 2022
 

Author contributions

Chengyuan Gu and Qian Wu contributed to manuscript preparation, data acquisition, and clinical treatment. Jingren Zhang contributed to the collection of clinical data and clinical treatment. Liqing Kang and Lei Yu contributed to CAR-T cell preparation. Depei Wu contributed to data acquisition and interpretation and design. Xiaofei Yang and Suning Chen contributed to the study design, data analysis, and manuscript revision.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The authors thank all members of the study team, the patients, and their family. This work was supported by research grants from the National Natural Science Foundation of China [81730003], National Science and Technology Major Project [2017ZX093040 21], National Key R&D Program of China [2019YFC0840604, 2017YFA0104502], National Natural Science Foundation of Jiangsu Province [BE2018652], Key R&D Program of Jiangsu Province [BE2019798], Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu Medical Outstanding Talents Project [JCRCA2016002], Jiangsu Provincial Key Medical Center [YXZXA2016002], Suzhou Science and Technology Program Project [SLT201911].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.